The historical rank and industry rank for Bright Minds Biosciences's PB Ratio or its related term are showing as below:
DRUG'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.85
Current: 2.85
During the past 6 years, Bright Minds Biosciences's highest PB Ratio was 2.85. The lowest was 0.00. And the median was 0.00.
DRUG's PB Ratio is ranked worse than 51.7% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs DRUG: 2.85
During the past 12 months, Bright Minds Biosciences's average Book Value Per Share Growth Rate was 777.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 53.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.30% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Bright Minds Biosciences was 53.00% per year. The lowest was -46.90% per year. And the median was 45.40% per year.
Back to Basics: PB Ratio
Bright Minds Biosciences (NAS:DRUG) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bright Minds Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bright Minds Biosciences (DRUG) has a PB Ratio of 2.87 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bright Minds Biosciences and its competitors. According to the industry distribution chart, Bright Minds Biosciences ranks #637 out of 1232 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Bright Minds Biosciences' PB Ratio too high?
Bright Minds Biosciences' current PB Ratio is 2.87. The Biotechnology industry median PB Ratio is 2.80. Bright Minds Biosciences' value of 2.87 is 2.5% above this industry median. Based on the distribution chart, Bright Minds Biosciences ranks #637 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bright Minds Biosciences ranks #637 out of 1232 companies for PB Ratio. This places Bright Minds Biosciences in the lower half of its industry. The industry median PB Ratio is 2.80. Bright Minds Biosciences' value of 2.87 is 2.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bright Minds Biosciences's current PB Ratio of 2.87 is 2.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bright Minds Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bright Minds Biosciences's current PB Ratio is 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current PB Ratio of 2.87. The current PB Ratio is 2.87 and 2.5% above the Biotechnology industry median of 2.80. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current PB Ratio is 2.87 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
